Overview

Oophorectomy, Estrogen Therapy and Cardiovascular Disease Risk in Young Women

Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Researchers are trying to assess the appropriate dose of estrogen for decreasing the risk of cardiovascular disease in women who have removal of their ovaries at a young age, before the age of 46 years.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Estrogens
Polyestradiol phosphate